Kristian Beran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kristian Beran has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- René Holm
Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, 5230 Odense, Denmark
7 shared publications - Jennifer Dressman
Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany
5 shared publications - Eline Hermans
Janssen Pharmaceutica NV, Pharmaceutical & Material Sciences, Beerse, Belgium
4 shared publications Kia Sepassi
Johnson & Johnson, Discovery Pharmaceutics
4 shared publicationsAlan Parr
BioCeutics LLC, Acworth, Georgia 30101, USA
2 shared publications- Atsushi Kambayashi
Faculty of Pharmaceutical Sciences, Tokyo University of Science, Japan
2 shared publications
Latest Publications
- 3 October 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (4) , 2215-2216
Voices in Molecular Pharmaceutics : Meet Dr. Kristian Beran, a Pharmaceutical Scientist Bridging Science and Business
- 3 October 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (4) , 2215-2216
Voices in Molecular Pharmaceutics : Meet Dr. Kristian Beran, a Pharmaceutical Scientist Bridging Science and Business
- Open Access
- 7 September 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (10) , 6067-6082
Canine Mdr1 Knockout MDCK Cells Reliably Estimate Human Small Intestinal Permeability (Peff) and Fraction Absorbed (fa)
Human intestinal permeability is a key determinant of the oral fraction absorbed (fa) of active pharmaceutical ingredients (APIs). This study evaluated the ability of an in-house canine Mdr1 (cMdr1) knockout (KO) Madin-Darby Canine Kidney (MDCK) cell line to correlate in vitro apparent permeability (Papp) with human small intestinal permeability (Peff). In vitro Papp values of 16 reference compounds with high, medium, or low permeabilities were measured in the in-house cMdr1 KO MDCK protocol under pH gradient (6.5 ⇒ 7.4) and pH equivalent conditions (7.4 ⇒ 7.4) and correlations with human Peff were established (R2 > 0.8). The correlations were subsequently used to estimate Peff and fa for six test APIs: acetaminophen, voriconazole, fedratinib, voxelotor, lemborexant, and istradefylline. The results for these APIs were compared against literature and permeability data from other methods routinely used in drug discovery and development. The projected Peff and fa values for the test APIs aligned well with literature permeabilities derived using other methods and clinical pharmacokinetic studies, respectively. This work highlights the usefulness of cMdr1 KO MDCK cells in permeability classification, especially for highly permeable APIs, and supports its broader use in both research and regulatory contexts.
- 7 September 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (10) , 6067-6082
Open AccessCanine Mdr1 Knockout MDCK Cells Reliably Estimate Human Small Intestinal Permeability (Peff) and Fraction Absorbed (fa)
Human intestinal permeability is a key determinant of the oral fraction absorbed (fa) of active pharmaceutical ingredients (APIs). This study evaluated the ability of an in-house canine Mdr1 (cMdr1) knockout (KO) Madin-Darby Canine Kidney (MDCK) cell line to correlate in vitro apparent permeability (Papp) with human small intestinal permeability (Peff). In vitro Papp values of 16 reference compounds with high, medium, or low permeabilities were measured in the in-house cMdr1 KO MDCK protocol under pH gradient (6.5 ⇒ 7.4) and pH equivalent conditions (7.4 ⇒ 7.4) and correlations with human Peff were established (R2 > 0.8). The correlations were subsequently used to estimate Peff and fa for six test APIs: acetaminophen, voriconazole, fedratinib, voxelotor, lemborexant, and istradefylline. The results for these APIs were compared against literature and permeability data from other methods routinely used in drug discovery and development. The projected Peff and fa values for the test APIs aligned well with literature permeabilities derived using other methods and clinical pharmacokinetic studies, respectively. This work highlights the usefulness of cMdr1 KO MDCK cells in permeability classification, especially for highly permeable APIs, and supports its broader use in both research and regulatory contexts.
- Open Access
- 25 December 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (2) , 1444-1454
Advantages of the refined developability classification system in early discovery
- 25 December 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (2) , 1444-1454
Open AccessAdvantages of the refined developability classification system in early discovery
- 14 November 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (2) , 660-680
Biowaiver monographs for immediate-release solid oral dosage forms: Voriconazole
- 14 November 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (2) , 660-680
Biowaiver monographs for immediate-release solid oral dosage forms: Voriconazole
- 23 October 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (2) , 644-659
Biowaiver monographs for immediate-release solid oral dosage forms: Lemborexant
- 23 October 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (2) , 644-659
Biowaiver monographs for immediate-release solid oral dosage forms: Lemborexant
- Open Access
- 5 October 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (12) , 3497-3517
Using the refined Developability Classification System (rDCS) to guide the design of oral formulations
- 5 October 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (12) , 3497-3517
Open AccessUsing the refined Developability Classification System (rDCS) to guide the design of oral formulations
- Open Access
- 21 June 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (9) , 2940-2946
A Stratified Analysis of Supersaturation and Precipitation Effects Based on the Refined Developability Classification System (rDCS)
- 21 June 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (9) , 2940-2946
Open AccessA Stratified Analysis of Supersaturation and Precipitation Effects Based on the Refined Developability Classification System (rDCS)
- Open Access
- 8 July 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (7) , 1909
Projection of Target Drug Particle Size in Oral Formulations Using the Refined Developability Classification System (rDCS)
Dissolution limitations to oral absorption can occur if the time required for dissolution is longer than the transit time across the small intestine and/or if dissolution is slower than the drug’s permeation through the gut wall. These limitations most often occur for poorly soluble drugs. A standard method for overcoming dissolution issues is to reduce the particle size of the (solid) drug. Building on the refined Developability Classification System (rDCS), this work establishes a novel set of equations with which the appropriate degree of particle size reduction needed to mitigate dissolution limitations to absorption can be calculated. According to the type of data available, the appropriate equation(s) for each situation can be applied. Three case examples are used to illustrate implementation of the equations: voriconazole, lemborexant and istradefylline. Although for voriconazole (rDCS Class I) target radius (rtarget) estimates indicate that particle size reduction is unnecessary, for lemborexant (rDCS Class I) a radius of ≤20 µm would be required to improve absorption. For istradefylline (rDCS Class IIb) the rtarget was approximately 12 µm. Results are commensurate with literature information for these three drugs, signaling that the equations are suitable for application to a wide variety of drug substances.
- 8 July 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (7) , 1909
Open AccessProjection of Target Drug Particle Size in Oral Formulations Using the Refined Developability Classification System (rDCS)
Dissolution limitations to oral absorption can occur if the time required for dissolution is longer than the transit time across the small intestine and/or if dissolution is slower than the drug’s permeation through the gut wall. These limitations most often occur for poorly soluble drugs. A standard method for overcoming dissolution issues is to reduce the particle size of the (solid) drug. Building on the refined Developability Classification System (rDCS), this work establishes a novel set of equations with which the appropriate degree of particle size reduction needed to mitigate dissolution limitations to absorption can be calculated. According to the type of data available, the appropriate equation(s) for each situation can be applied. Three case examples are used to illustrate implementation of the equations: voriconazole, lemborexant and istradefylline. Although for voriconazole (rDCS Class I) target radius (rtarget) estimates indicate that particle size reduction is unnecessary, for lemborexant (rDCS Class I) a radius of ≤20 µm would be required to improve absorption. For istradefylline (rDCS Class IIb) the rtarget was approximately 12 µm. Results are commensurate with literature information for these three drugs, signaling that the equations are suitable for application to a wide variety of drug substances.